Greetings, and welcome to the AirSculpt Technologies first quarter fiscal year twenty 2026 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Allison Malkin, partner with ICR. Thank you. You may begin. Good morning, everyone. Thank you for joining us to discuss AirSculpt Technologies results for the first quarter of fiscal year 2026. Joining me today on this call are Yogi Jashnani, Chief Executive Officer, and Michael Arthur, Chief Financial Officer. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth. Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from the currently projected results are described in this morning's press release and the reports we will file with the SEC, all of which can be found on our website at investors.airsculpt.com. We undertake no obligation to revise or update any forward-looking statements or information except as required by law. During our call today, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-K, which is available on our website. With that, I'll turn the call over to Yogi. Thank you, Allison, and good morning, everyone. Nice to speak with you and share our positive start to the year. For this morning's call, I will start with a review of our first quarter performance, followed by an update on strategic priorities which are driving our return to growth. Michael will then take you through our first quarter financials and 2026 outlook. The first quarter marked a key turning point for our company. We stabilized revenue year-over-year and delivered positive same-center sales for the first time in over two years. We expanded gross margin and made important investments in marketing and talent. At the same time, we reduced non-consumer-facing expenses, which combined generated healthy profitability. We also strengthened our balance sheet, ending the quarter with over $16 million in cash and leverage below 2.5x, a reduction of over 1.0 compared to the same time last year. Our positive start to the year reflects the success of the transformational work completed in 2025. This gives us a solid foundation from which to grow. While still early, we are encouraged by the progress made and the trajectory of our business as we enter the second quarter. Today, we are well-positioned in an attractive and growing industry with the right team and strategies in place to capitalize on the meaningful opportunity ahead. We remain confident in our outlook and our ability to deliver sustained long-term profitable growth and value creation for our shareholders. Let me now share highlights of our progress on the strategic priorities that have repositioned our company for sustainable and consistent growth. As a reminder, these are introducing new services to capture our GLP-1 market opportunity, enhancing our sales and marketing strategy, and maintaining strong financial discipline. First, introducing new services to capture our GLP-1 market opportunity. GLP-1 medications continue to fundamentally reshape the aesthetics landscape. The GLP-1 user base is expected to grow from approximately 5 million in 2023 to 25 million by 2030, a roughly 400% increase that creates a significant and durable tailwind for body contouring in a $200 billion GLP-1 market. With 63% of these patients indicating interest in treatment, this translates to nearly 19 million potential patients pursuing body contouring or related procedures. AirSculpt is a desired solution for these patients. Our minimally invasive procedures have little downtime and address the need for additional fat removal, which is the mainstay of our business and has been a catalyst to expand our offering to address GLP-1 user needs. Our recently introduced procedures, such as standalone skin tightening and skin removal, are the latest examples. Combined, we are effectively addressing the side effects from GLP-1 use and helping patients achieve their desired look. While not a meaningful contributor today, traction for these newer procedures is growing. We completed over 150 skin excision procedures in Q1 alone. Combined with fat removal and fat transfer, these procedures have the potential to unlock more than $100 million in long-term revenue across our existing centers. Second, enhancing our sales and marketing strategy. The marketing initiatives we launched at the end of 2025 are translating into more consistent demand. We continue to see benefits from our expanded media mix, including Connected TV, increased influencer engagement, and more targeted campaigns across skin tightening and skin removal. At the same time, improvements to our digital funnel and website are driving higher quality leads and better conversion. Sales execution has improved as well. Through better training, deeper product understanding, and aligned incentives, our teams are converting demand more effectively. As a result, we are seeing improvement in conversion rates and revenue. Third, maintaining strong financial discipline. Debt reduction remains a key focus of our capital allocation strategy. As discussed in our last call, we repaid nearly $30 million of debt over the last five quarters, bringing our leverage below 2.5 turns, a reduction of over one turn. We are also in process to refinance our term loan and look forward to sharing the details when we report our Q2 results. As we look ahead, we remain focused on continuing to advance our strategic priorities and are pleased to begin our seasonally strongest quarter of the year with continuing positive momentum. In the second quarter, we are targeting sequential improvement in same-store sales as we build upon the progress made in Q1. In summary, we had a strong start to 2026 as our actions to reposition the business are bearing fruit. AirSculpt has always had a strong differentiation in the marketplace given its highly effective and minimally invasive body contouring procedures. Our Q1 results demonstrate that our strategic priorities are working. We remain focused on building this momentum and driving sustainable growth to create value for our shareholders. With that, I will now pass it over to Michael. Thank you, Yogi. Good morning, everyone. As Yogi mentioned, our first quarter results are clear evidence that the improvements we made to our business last year are driving our growth today. We are very pleased with our start to 2026 and the momentum we continue to see in Q2. Turning to the first quarter. Revenue for the quarter was $39.4 million, flat versus the prior year quarter and up 1% on a same-store basis, excluding the impact of London. Same-store revenue growth was driven by a higher case volume. This also reflects a 19% sequential improvement. Cost of services was $15.6 million, resulting in gross margin expansion of roughly 1% to 60% of revenue. Selling, General, Administrative expenses were approximately $22.6 million, an increase of approximately $800,000 compared to prior year. This reflects a deliberate choice to increase investment in marketing and brand development, which contributed to our first quarter revenue growth and the first time in nine quarters. Cost discipline continues to be a priority. Equally important is being strategic about where we invest those savings to drive long-term shareholder value. Customer acquisition costs for the quarter was roughly $3,400 per case, compared to $3,130 in the prior year quarter. Adjusted EBITDA was $3.3 million or roughly 8.4% of revenue, a decrease from 9.5% in the prior year. Turning to our balance sheet. As of 31st March, 2026, cash was $16.7 million. We paid down $11 million of debt in the quarter, resulting in gross debt outstanding of approximately $46 million at quarter end. Under our credit agreement, we are in compliance with all covenants, and we are making progress to refinance our term loan. We look forward to sharing the details with you when we report our Q2 results. Cash flow from operations for the quarter was approximately $5 million, compared to approximately $1 million in 2025. Turning to our outlook. We are reaffirming our full year 2026 outlook and continue to expect revenue in the range of $151 million-$157 million and Adjusted EBITDA in the range of $15 million-$17 million. We continue to expect the business to build momentum as the year progresses, with the midpoint of our revenue range reflecting approximately 3% comparable growth excluding London from 2025. As a reminder, our London center contributed 1% to comps in 2025. Our guidance does not contemplate any de novos in the period. As we enter Q2, a seasonally stronger quarter, we expect to deliver sequential improvement in both revenue and EBITDA in absolute $ versus Q1. The initiatives we have in place have strengthened the fundamentals of the business, providing us with solid platform to deliver long-term growth. Looking ahead, we continue to monitor the broader macro environment, including factors such as consumer sentiment. We will remain agile in managing the business as conditions evolve. As I wrap up, we are pleased with our strong start to the year and the momentum in the business. We remain focused on disciplined execution. We are well-positioned to deliver on our full-year objectives. With that, I'll turn it back to Yogi for closing remarks. Thank you, Michael. In conclusion, we are pleased with our start to 2026 and the acceleration in our business with our enhanced sales and marketing strategy and new procedures driving growth. We are delivering on what we set out to do and are intently focused on building upon our positive performance and achieving our goal to generate long-term sustainable, profitable growth and value creation for our shareholders. With that, I'd like to turn over the call to the operator to begin the Q&A portion of the call. Thank you. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. We ask that you each keep to one question and one follow-up and invite you to rejoin the queue for additional questions. Our first question comes from the line of Sam Eiber with BTIG. Please proceed with your question. Hi. Good morning. Thanks for taking the questions here. Yogi, maybe I can start on the Q1 results. You know, clearly it looks like, you know, demand has stabilized. Revenue results are starting to trend back up in the right direction. I guess, you know, what's been working well so far in the quarter? You know, how much would you attribute it to the enhanced marketing strategy versus the new skin tightening services versus maybe just a better demand environment overall for body contouring procedures? Sam, thank you so much for the question. We, we see that, first of all, obviously we are pleased with the results in Q1 and continue to build on that. We've seen that it was the actions we took and we are taking, which is driving the improvements, primarily around the enhanced marketing strategy. What that's doing, not just to leads and consults, but showing up in revenue as well. All of those actions and the underlying performance metrics that are going into it, are working. The building blocks are there to deliver growth. As far as the expanded procedures are concerned, we continue to be excited about the early progress from the pilot and the learnings we've gained to date around skin removals. They're still in pilot phase and being rolled out across centers, so they've not been a meaningful incremental contributor yet to what we are doing. The consumer environment is still I would say challenging, especially for considered purchases. In summary, the improvement we are seeing we are able to tie back directly to the enhancements to sales and marketing and all of the foundational work we did in 2025. We have more upside, particularly as we go through the year, particularly as we see the new procedures expand and go from there. Okay. That's really helpful. Thank you, Yogi. Maybe, just a quick follow-up on, you know, the balance sheet now, strengthened. You know, Do you look at maybe the opportunity to look at opening de novo centers again later this year? Is that still maybe a 2027 dynamic? I guess, how should we be thinking about, you know, reinvesting back into opening new centers again? Hi, Sam Eiber. This is Michael Arthur. Yeah, I mean, as of right now, our plan doesn't contemplate any de novos in 2026. You know, we do continue to be excited about the long-term center opportunity, and we'll open de novos at the appropriate time. In the short term, as Yogi kind of mentioned, we're still, you know, really focused on improving our same-center sales growth. You know, it's our number one priority, Q1 is a big step in that, right, with the positive comp growth. Right now that's our short-term focus. Certainly de novos is an opportunity for us, but nothing contemplated in the year. Okay. Really helpful. Thanks for taking the questions and nice start to the year here. Thank you, Sam. Thank you. Ladies and gentlemen, once again, if you'd like to ask a question, please press star one on your telephone keypad. We'll pause a moment to allow for other questions. Thank you. Ladies and gentlemen, that concludes our question and answer session. I'll turn the floor back to Mr. Jashnani for any final comments. Thank you, Melissa, and thank you everyone again for joining us. We look forward to speaking with you when we report Q2 and meeting with some of you at upcoming investor conferences. Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.